IS

Icahn School of Medicine at Mount Sinai at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Icahn School of Medicine at Mount Sinai takes part in 3 sessions at ESMO 2026 in Madrid. Its program centres on bladder cancer and on how inflammation links ageing with cancer. It presents molecular subtypes tied to treatment outcomes in muscle-invasive bladder cancer from the NIAGARA trial, and natural killer cell functions induced by cytomegalovirus that may improve outcomes.

Organization

ESMO 2026 Attendance

IS

Icahn School of Medicine at Mount Sinai

New York, NY

University & institute

Medical school of the Mount Sinai Health System in New York City, with a cancer institute.

Abstract

Sat Oct 24
11:15–11:20

4741RO - Exploratory Analysis of Molecular Subtypes and Association With Treatment Outcomes in Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC) From NIAGARA

Rapid oral 1: Genitourinary tumours, renal and urothelial

Genitourinary cancers

Abstract

Sun Oct 25
15:47–15:57

4239O - CMV-induced adaptive NK cell functions to improve bladder cancer patient outcomes

Proffered paper 1: Basic science and translational research

Keynote

Mon Oct 26
12:20–12:45

Ageing and cancer: An inevitable fate or a preventable consequence of inflammation?

Keynote lecture 4

Instantly find 20 buyers from Icahn School of Medicine at Mount Sinai

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction